Biovail ( BVF) acquired the U.S. rights to Ativan and Isordil from Wyeth ( WYE) for $130 million and annual payments related to a three-year supply agreement.

Sales of Ativan and Isordil in the U.S. exceeded $50 million in 2002.

Ativan is a benzodiazepine, indicated for managing anxiety disorders. The market for anxiety treatments reached more than $11 billion in 2002.

Isordil is a nitrate designed to prevent angina pectoris due to coronary artery disease. Sales of nitrate products were above $360 million last year.

"The acquisition of Ativan and Isordil is another example of the execution of Biovail's business model," the pharmaceutical company said in a press release. "These products have tremendous brand equity and strategically complement two of the company's target therapeutic areas."

Shares of Biovail were rising 3.4% to $48.22 in recent New York Stock Exchange trading. Wyeth was down 16 cents at $43.69.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain